Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus

By sjmartinez • March 15, 2025

Zhang Y, Tedeschi SK, Abhishek A, Hensey O, Grossberg D, Cai K, Shea B, Singh JA, Christensen R, Serban T, Cipolletta E, Parperis K, Diaz-Torne C, McCarthy GM, Becce F, Gheita TA, Sirotti S, Christiansen SN, Coronel L, Stamp LK, Abdel-Fattah YH, Pascart T, Filippou G, Hong LE, FitzGerald J, Dalbeth N. Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus. Semin Arthritis Rheum. 2025 Mar 7;72:152669. doi: 10.1016/j.semarthrit.2025.152669. Epub ahead of print. PMID: 40086154.

Tags: calcium pyrophosphate deposition disease, Core domain set, Delphi, Domain, OMERACT, Publications, Rheumatology, Veterans Administration

Related Posts

Early cellular events of osteomucosal healing in the tooth extraction socket

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]

Ventricular Tachycardia Predicts All-Cause Mortality and Nonsudden Cardiac Death in Nonischemic Cardiomyopathy

Omara S, Jensen TN, Koeber L, Thune JJ, Pehrson S, Mertens B, Tedrow UB, Hindricks G, Ebert M, Carbucicchio C, Berruezo A, Vaseghi M, Shivkumar[...]

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the[...]